Over the past three years, the COVID-19 pandemic made long-standing medical product supply chain vulnerabilities even more obvious, including the potential for drug shortages and quality concerns. While the U.S.

Generic medicines have benefited millions of Americans and saved trillions of dollars.

The issue of addressing potential nitrosamine impurities in medicines has been the focus at events taking place around the globe in recent months and will continue to do so throughout 2023.

The quality of excipients in medicines – which make up every part of a drug other than the active pharmaceutical ingredient (API) – is critical to a resilient medicines supply chain, panelists agreed at an April 25 session of the Asia-Pacific Economic Cooperation (